AU8814798A - Methods for analyzing ltc4 synthase polymorphisms and diagnostic use - Google Patents

Methods for analyzing ltc4 synthase polymorphisms and diagnostic use

Info

Publication number
AU8814798A
AU8814798A AU88147/98A AU8814798A AU8814798A AU 8814798 A AU8814798 A AU 8814798A AU 88147/98 A AU88147/98 A AU 88147/98A AU 8814798 A AU8814798 A AU 8814798A AU 8814798 A AU8814798 A AU 8814798A
Authority
AU
Australia
Prior art keywords
polymorphisms
analyzing
methods
diagnostic use
ltc4 synthase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU88147/98A
Other languages
English (en)
Inventor
John Edward Norris Morten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Syngenta Ltd
Original Assignee
Zeneca Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zeneca Ltd filed Critical Zeneca Ltd
Publication of AU8814798A publication Critical patent/AU8814798A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU88147/98A 1997-08-22 1998-08-18 Methods for analyzing ltc4 synthase polymorphisms and diagnostic use Abandoned AU8814798A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9717766.1A GB9717766D0 (en) 1997-08-22 1997-08-22 Methods
GB9717766 1997-08-22
PCT/GB1998/002468 WO1999010529A1 (en) 1997-08-22 1998-08-18 Methods for analyzing ltc4 synthase polymorphisms and diagnostic use

Publications (1)

Publication Number Publication Date
AU8814798A true AU8814798A (en) 1999-03-16

Family

ID=10817852

Family Applications (1)

Application Number Title Priority Date Filing Date
AU88147/98A Abandoned AU8814798A (en) 1997-08-22 1998-08-18 Methods for analyzing ltc4 synthase polymorphisms and diagnostic use

Country Status (6)

Country Link
US (2) US6316196B1 (enExample)
EP (1) EP1007738A1 (enExample)
JP (1) JP2001514013A (enExample)
AU (1) AU8814798A (enExample)
GB (2) GB9717766D0 (enExample)
WO (1) WO1999010529A1 (enExample)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6881571B1 (en) 1998-03-11 2005-04-19 Exonhit Therapeutics S.A. Qualitative differential screening
FR2798392B1 (fr) * 1999-09-13 2005-07-15 Exonhit Therapeutics Sa Marqueurs genetiques de la toxicite, preparation et utilisations
AU3793701A (en) * 1999-11-29 2001-06-04 Orchid Biosciences, Inc. Methods of identifying optimal drug combinations and compositions thereof
WO2001079560A2 (en) * 2000-04-17 2001-10-25 Glaxo Group Limited Medicine response assay in respiratory disease
CN1329012A (zh) * 2000-06-21 2002-01-02 上海博德基因开发有限公司 一种新的多肽——烟酰胺腺嘌呤脱氧二核苷酸依赖性白三烯b412－羟基脱氢酶36和编码这种多肽的多核甘酸
US20050009023A1 (en) * 2001-07-03 2005-01-13 Neil Richtand Glucocorticoid-induced receptor and methods of use
CA2458303A1 (en) * 2001-09-17 2003-03-27 Janssen Pharmaceutica N.V. Brain expressed cap-2 gene and protein associated with bipolar disorder
US7833706B2 (en) * 2003-01-30 2010-11-16 Celera Corporation Genetic polymorphisms associated with rheumatoid arthritis, methods of detection and uses thereof
US20050019795A1 (en) * 2003-04-24 2005-01-27 Aventis Pharma Deutschland Gmbh Analysis and use of PAR1 polymorphisms for evaluating the risk of cardiovascular disorders
EP2186913B1 (en) * 2003-11-26 2016-02-10 Celera Corporation Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
US20090297563A1 (en) * 2004-10-27 2009-12-03 Anders Borglum Diagnosis And Treatment of Immune-Related Diseases
WO2007059348A2 (en) * 2005-11-17 2007-05-24 Third Wave Technologies, Inc. Compositions and methods for detecting an hcv-1 subtype
EP2027284A2 (en) * 2006-05-18 2009-02-25 Sanofi-Aventis Use of adamts4 gene and protein polymorphisms
CA2653794C (en) * 2006-06-30 2012-05-01 Clifford L. Librach Method of detecting preeclampsia
WO2008033239A2 (en) * 2006-09-11 2008-03-20 Applera Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
WO2008039941A2 (en) 2006-09-27 2008-04-03 The Government Of The Usa As Represented By The Secretary Of The Dpt. Of Health And Human Services Scgb3a2 as a growth factor and anti-apoptotic agent
US7811765B2 (en) * 2006-10-12 2010-10-12 Children's Hospital & Research Center At Oakland Methods and compositions for determining predisposition to inflammation-mediated cardiovascular disease
US20080248470A1 (en) * 2007-04-04 2008-10-09 Sungkyunkwan University Foundation For Corporate Collaboration Genetic screening for predicting antidepressant drug response based on the monoamine transporter gene polymorphism combination
US9079961B2 (en) * 2007-05-25 2015-07-14 Japanese Red Cross Society GPIIIa gene
WO2009052160A1 (en) * 2007-10-19 2009-04-23 Marshfield Clinic Method for administering anticoagulation therapy
WO2009061734A1 (en) * 2007-11-05 2009-05-14 The Government Of The United States Of America As Represented By The Secretary Of The Deparment Of Health And Human Services Identification of subjects likely to benefit from statin therapy
US7947451B2 (en) * 2007-11-30 2011-05-24 Celera Corporation Genetic polymorphisms associated with psoriasis, methods of detection and uses thereof
US10023913B2 (en) * 2008-01-29 2018-07-17 The Johns Hopkins University SR-BI as a predictor of elevated high density lipoprotein and cardiovascular disease
US20110112186A1 (en) * 2008-02-29 2011-05-12 Isis Innovation Limited Diagnostic methods
US9817001B2 (en) 2008-05-27 2017-11-14 Boston Heart Diagnostics Corporation Methods for determining LDL cholesterol treatment
US8470541B1 (en) 2008-09-27 2013-06-25 Boston Heart Diagnostics Corporation Methods for separation and immuno-detection of biomolecules, and apparatus related thereto
DE102008064509B4 (de) * 2008-12-22 2017-06-08 Robert Bosch Gesellschaft mbH für medizinische Forschung Verfahren zur Bestimmung der Prädisposition für Morbus Crohn
CA2706021C (en) * 2009-05-28 2018-10-16 Institut De Cardiologie De Montreal Genetic predictors of international normalized ratio (inr) fluctuation with warfarin therapy
WO2011068610A1 (en) * 2009-12-01 2011-06-09 Quest Diagnostics Investments Incorporated Methods for detecting risk of myelodysplastic syndrome by genotypic analysis
US9732389B2 (en) 2010-09-03 2017-08-15 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with prostate cancer risk
WO2012082912A2 (en) * 2010-12-14 2012-06-21 Tufts Medical Center, Inc. Markers related to age-related macular degeneration and uses therefor
US9534256B2 (en) * 2011-01-06 2017-01-03 Wake Forest University Health Sciences Methods and compositions for correlating genetic markers with risk of aggressive prostate cancer
AU2012322018B2 (en) 2011-10-13 2017-09-21 Boston Heart Diagnostics Compositions and methods for treating and preventing coronary heart disease
US9828624B2 (en) 2013-07-24 2017-11-28 Boston Heart Diagnostics Corporation Driving patient compliance with therapy
US10098893B2 (en) * 2013-10-03 2018-10-16 Northwestern University Methods of administering a trace amine-associated receptor 1 (TAAR1) agonist to patients having the minor allele of the single nucleotide polymorphism rs2237457
EP3149487B1 (en) * 2014-05-29 2020-02-12 Geneticure LLC Improved therapeutic regimen for hypertension
US11761043B2 (en) 2014-05-29 2023-09-19 Geneticure Inc. Machine assay and analysis for selecting antihypertensive drugs
US10260108B2 (en) * 2014-11-04 2019-04-16 University of Pittsburgh—of the Commonwealth System of Higher Education PARP genomic variants conferring resistance and sensitization to chemotherapy under inhibition
CA2968221A1 (en) 2014-11-17 2016-05-26 Boston Heart Diagnostic Corporation Cardiovascular disease risk assessment

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993018178A1 (en) * 1992-03-13 1993-09-16 The Children's Hospital Of Philadelphia DIAGNOSIS OF β-THALASSEMIA USING A MULTIPLEX AMPLIFICATION REFRACTORY MUTATION SYSTEM
CA2136239C (en) 1992-06-15 2004-10-05 Donald W. Nicholson Leukotriene c4 synthase
WO1995032280A1 (en) * 1994-05-20 1995-11-30 Brigham And Women's Hospital Dna encoding human leukotriene c4 synthase, polypeptides, and uses therefor
US5952210A (en) * 1994-06-03 1999-09-14 G. D. Searle & Company Nucleic acids and expression vectors encoding human leukotiene C4 synthase
AU2927797A (en) 1996-05-06 1997-11-26 Brigham And Women's Hospital 5-lipoxygenase gene polymorphisms and their use in classifying patients

Also Published As

Publication number Publication date
US20030077592A1 (en) 2003-04-24
EP1007738A1 (en) 2000-06-14
GB2342717A (en) 2000-04-19
WO1999010529A1 (en) 1999-03-04
GB9717766D0 (en) 1997-10-29
JP2001514013A (ja) 2001-09-11
US6316196B1 (en) 2001-11-13
GB0001527D0 (en) 2000-03-15
GB2342717B (en) 2001-11-28

Similar Documents

Publication Publication Date Title
AU8814798A (en) Methods for analyzing ltc4 synthase polymorphisms and diagnostic use
AU9397498A (en) Diagnostic device and method
AU4995999A (en) Treatment for schizophrenia and other dopamine system dysfunctions
AU5560199A (en) Adapter directed expression analysis
AU9790198A (en) Compounds and methods
AUPP398898A0 (en) Diagnostic method and apparatus
AU4322999A (en) Methods and compositions for diagnosing tauopathies
AU3883899A (en) Automated tooth shade analysis and matching system
AU2031700A (en) Stereotactic apparatus and methods
AU5142699A (en) Methods and compositions for increasing insulin sensitivity
AU2030000A (en) Methods and compositions for identifying receptor effectors
AU1465801A (en) Methods for cancer prognosis and diagnosis
AU3849999A (en) Endo-beta-n-acetylglucosaminidase gene
AU7368798A (en) Tissue analysis apparatus
AU9301998A (en) Composition and methods using galectin-1
AU6105199A (en) Diagnostic method
AU7571298A (en) Systems and methods for analyzing phantom images
AU1138699A (en) Dna demethylase, therapeutic and diagnostic uses thereof
AU1059300A (en) Data analysis
AU7965398A (en) Methods and solutions for cleaning dentures
ZA9710934B (en) Compositions and methods for administering pneumococal dna
AU8919098A (en) Fumonosin resistance
AU2314099A (en) Secure exam method
AUPO982097A0 (en) Methods and compositions for use therein
AU1113499A (en) Compositions and methods for identifying and testing therapeutics against hsv infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase